NRX Pharmaceuticals Inc

NASDAQ:NRXPUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The Company has two lead compounds, NRX-100, a proprietary presentation of ketamine and NRX-101, a fixed-dose combination of D-cycloserine (DCS) and lurasidone. The Company is developing NRX-101, a Food and Drug Administration (FDA)-designated investigational therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRX-101 is a combined NMDA/5-HT2A-targeted medicine designed to address both depression and suicidal ideation, consisting of an oral, fixed dose combination of DCS and lurasidone. Its NRX-100 is racemic ketamine, which is a generic anesthetic. The Company is also engaged in the development of its new product, NRX-102.

Contact Information

Headquarters

1201 ORANGE STREET, SUITE 600WILMINGTON, DE, United States 19801

Phone

484-254-6134

Fax

302-575-1642

Executives

Chairman of the Board, Chief Scientific Officer

Jonathan Javitt

Interim Chief Financial Officer

Richard Narido

CMC and Technical Operations Advisor

Riccardo Panicucci

Independent Director

Patrick Flynn

Independent Director

Sharon Glied